We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Read MoreHide Full Article
Key Takeaways
{\"0\":\"JNJ raised its 2025 sales outlook by $2B at the midpoint after beating Q2 earnings and revenue estimates.\",\"1\":\"Innovative Medicine and MedTech segments are expected to see stronger growth in 2H25.\",\"2\":\"New launches like Carvykti and Tecvayli, plus MedTech adoption support, raised full-year EPS guidance.\"}
Johnson & Johnson (JNJ - Free Report) announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity (“LOE”) of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China.
But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds.
The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million.
J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer.
In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025.
We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026.
Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech (BNTX - Free Report) for the global co-development and co-commercialization of BNTX’s investigational bispecific antibody BNT327 across numerous solid tumor types.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe.
Image: Bigstock
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Key Takeaways
Johnson & Johnson (JNJ - Free Report) announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity (“LOE”) of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China.
But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds.
The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million.
J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer.
In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025.
We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026.
ABBV & BMY Also Raise Guidance
Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie (ABBV - Free Report) and Bristol-Myers (BMY - Free Report) . ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.’
Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech (BNTX - Free Report) for the global co-development and co-commercialization of BNTX’s investigational bispecific antibody BNT327 across numerous solid tumor types.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry.
From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68.
The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe.
J&J has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.